552 Evaluation of the pharmacokinetic (PK) interactions between cetuximab and irinotecan in patients with epidermal growth factor receptor (EGFR)-expressing advanced solid tumors. Results of a phase I study

Growth Factor ◽

Epidermal Growth Factor ◽

Phase I ◽

Solid Tumors ◽

Phase I Study ◽

Growth Factor Receptor ◽

Advanced Solid Tumors ◽

Faculty Opinions recommendation of Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.14346.471799 ◽

2006 ◽

Author(s):

Jeffrey Evans

Keyword(s):

Growth Factor ◽

Epidermal Growth Factor ◽

Phase I ◽

Solid Tumors ◽

Phase I Study ◽

Growth Factor Receptor ◽

Advanced Solid Tumors ◽

Irreversible Inhibitor ◽

A First‐in‐Human Phase I Study of GC1118, a Novel Anti‐Epidermal Growth Factor Receptor Antibody, in Patients with Advanced Solid Tumors

The Oncologist ◽

10.1634/theoncologist.2019-0294 ◽

2019 ◽

Vol 24 (8) ◽

pp. 1037 ◽

Cited By ~ 1

Author(s):

Do‐Youn Oh ◽

Keun‐Wook Lee ◽

Sae‐Won Han ◽

Jin Won Kim ◽

Jung‐Won Shin ◽

...

Keyword(s):

Growth Factor ◽

Epidermal Growth Factor ◽

Phase I ◽

Solid Tumors ◽

Phase I Study ◽

Growth Factor Receptor ◽

Advanced Solid Tumors ◽

Receptor Antibody ◽

Faculty of 1000 evaluation for Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors.

F1000 - Post-publication peer review of the biomedical literature ◽

10.3410/f.718203593.793488507 ◽

2013 ◽

Author(s):

Ana Maria Gonzalez-Angulo

Keyword(s):

Growth Factor ◽

Epidermal Growth Factor ◽

Phase I ◽

Solid Tumors ◽

Phase I Study ◽

Growth Factor Receptor ◽

Human Epidermal Growth Factor ◽

A phase I study of the chimeric monoclonal anti-epidermal growth factor receptor (EGFR) antibody cetuximab as a single agent in subjects from Japan with advanced solid tumors: Safety, pharmacokinetics (PK)

Journal of Clinical Oncology ◽

10.1200/jco.2005.23.16_suppl.3209 ◽

2005 ◽

Vol 23 (16_suppl) ◽

pp. 3209-3209 ◽

Cited By ~ 2

Author(s):

H. Yasui ◽

K. Shirao ◽

N. Yamamoto ◽

Y. Shimada ◽

Y. Yamada ◽

...

Keyword(s):

Growth Factor ◽

Epidermal Growth Factor ◽

Phase I ◽

Phase I Study ◽

Single Agent ◽

Growth Factor Receptor ◽

Advanced Solid Tumors ◽

Epidermal Growth ◽

Egfr Antibody

A Phase I Study of an Anti-epidermal Growth Factor Receptor Monoclonal Antibody for the Treatment of Malignant Gliomas

Neurosurgery ◽

10.1097/00006123-199609000-00009 ◽

1996 ◽

Vol 39 (3) ◽

pp. 478-483 ◽

Cited By ~ 11

Author(s):

Thierry Faillot ◽

Henri Magdelénat ◽

Essam Mady ◽

Paul Stasiecki ◽

Denis Fohanno ◽

...

Keyword(s):

Monoclonal Antibody ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Phase I ◽

Phase I Study ◽

Malignant Gliomas ◽

Growth Factor Receptor ◽

Epidermal Growth ◽

Receptor Monoclonal Antibody

A Phase I Study of Interleukin 12 with Trastuzumab in Patients with Human Epidermal Growth Factor Receptor-2-Overexpressing Malignancies

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-04-0265 ◽

2004 ◽

Vol 10 (15) ◽

pp. 5027-5037 ◽

Cited By ~ 73

Author(s):

Robin Parihar ◽

Padma Nadella ◽

Adrian Lewis ◽

Rhonda Jensen ◽

Carrie De Hoff ◽

...

Keyword(s):

Growth Factor ◽

Epidermal Growth Factor ◽

Phase I ◽

Phase I Study ◽

Growth Factor Receptor ◽

Interleukin 12 ◽

Human Epidermal Growth Factor ◽

A randomized phase I study of the humanized anti-epidermal growth factor receptor (EGFR) monoclonal antibody EMD 72000 in subjects with advanced gastrointestinal cancers

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.14_suppl.3018 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 3018-3018 ◽

Cited By ~ 5

Author(s):

T. Trarbach ◽

T. Beyer ◽

N. Schleucher ◽

J. Stattaus ◽

S. P. Mueller ◽

...

Keyword(s):

Monoclonal Antibody ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Phase I ◽

Phase I Study ◽

Growth Factor Receptor ◽

Gastrointestinal Cancers ◽

Safety and Immunogenicity of a Human Epidermal Growth Factor Receptor 1 (HER1)-Based Vaccine in Prostate Castration-Resistant Carcinoma Patients: A Dose-Escalation Phase I Study Trial

Frontiers in Pharmacology ◽

10.3389/fphar.2017.00263 ◽

2017 ◽

Vol 8 ◽

Cited By ~ 5

Author(s):

Iraida Caballero

Keyword(s):

Growth Factor ◽

Epidermal Growth Factor ◽

Phase I ◽

Dose Escalation ◽

Phase I Study ◽

Growth Factor Receptor ◽

Human Epidermal Growth Factor ◽

Castration Resistant ◽

Results of a phase I trial of the humanized anti epidermal growth factor receptor (EGFr) monoclonal antibody emd 72000 in patients with EGFr expressing solid tumors

European Journal of Cancer ◽

10.1016/s0959-8049(02)80814-0 ◽

2002 ◽

Vol 38 ◽

pp. S53

Keyword(s):

Monoclonal Antibody ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Phase I ◽

Solid Tumors ◽

Phase I Trial ◽

Growth Factor Receptor ◽

Phase I study of humanized IgG1 anti-epidermal growth factor receptor (EGFR) monoclonal antibody EMD 72000 plus gemcitabine (Gem) in advanced pancreatic cancer

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.90140.3061 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 3061-3061

Author(s):

U. Graeven ◽

I. Vogel ◽

B. Killing ◽

S. Hinz ◽

W. Von Bernstorff ◽

...

Keyword(s):

Pancreatic Cancer ◽

Monoclonal Antibody ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Phase I ◽

Phase I Study ◽

Advanced Pancreatic Cancer ◽

Growth Factor Receptor ◽